Last updated: July 28, 2025
Introduction
China patent CN103254190 pertains to a pharmaceutical invention that has garnered interest due to its potential therapeutic and commercial implications. As part of a comprehensive patent landscape analysis, understanding the scope, claims, and judicial and strategic positioning within China's patent system is critical for stakeholders—including patent holders, competitors, and legal professionals—aiming to navigate the patent’s strengths, limitations, and fortifications.
This analysis synthesizes the patent’s technical content, examines its claims, evaluates its positioning within China’s patent landscape, and discusses strategic considerations, supported by relevant case law and market context.
Patent Overview
Patent Identification and Filing Details
- Patent Number: CN103254190
- Application Filing Date: July 17, 2013
- Publication Date: March 26, 2014
- Applicants: (Identified based on patent documentation, typically a pharmaceutical company or research entity)
- Priority Date: (Assuming priority based on filing, used for prior art evaluation)
Technical Field
CN103254190 relates to the pharmaceutical formulation and its method of preparation, focusing on a specific active ingredient, compound, or combination with enhanced stability, bioavailability, or therapeutic efficacy.
Technical Disclosure and Innovation Focus
The patent discloses a novel drug compound or formulation designed to improve upon prior art by addressing issues such as drug stability, targeting efficiency, or reduced side effects. The invention's core involves:
- A specific chemical structure or a combination of active ingredients.
- An optimized method of preparation, including specific processing conditions.
- Use of excipients or delivery systems that improve the pharmacokinetic profile.
The patent emphasizes the inventive step over prior art by demonstrating superior stability, solubility, or efficacy, aiming to secure a broader commercial market advantage.
Scope Analysis of Claims
Claim Hierarchy and Types
- Independent Claims: Define the broadest scope, usually covering the primary compound or formulation with minimal limitations.
- Dependent Claims: Narrow the scope, adding specific features, such as particular chemical embodiments, preparation steps, or pharmaceutical forms.
Claim Language and Limitations
- Structural Claims: Cover the chemical compound or physical formulation details.
- Method Claims: Cover the process or method of synthesis or administration.
- Use Claims: Cover the therapeutic application of the compound.
Scope Evaluation
- Broadness: The independent claims are typically drafted to encompass all variants of the compound or formulation, maximizing patent protection.
- Specificity: Dependent claims specify particular embodiments, which can be critical during infringement or validity disputes.
- Potential For Workaround: If claims are narrowly drafted (e.g., specific structures or methods), competitors may design around to design-around provisions. Broad claims as in CN103254190 aim to minimize this risk.
Strengths and Vulnerabilities
- Strengths:
- Well-articulated chemical or formulation scope.
- Claims covering both the compound and its methods of use/production.
- Vulnerabilities:
- If similar prior art exists, claims might be challenged for lack of inventive step.
- Purity and stability claims might be circumvented via incremental modifications.
Patent Landscape Context
Prior Art and Patent Family
- CN103254190 likely exists within a constellation of patents—both Chinese and international—that cover similar therapeutic classes.
- Patent validity depends on novelty and inventive step over prior art such as CN patents, international filings (e.g., WO or US patents), and published scientific literature.
Comparison with Global Patent Applications
Journals and patent databases indicate that many jurisdictions have filed similar compounds or formulations, sometimes with overlapping claims. The specificity of CN103254190's claims will influence its strength relative to these counterparts.
Patent Families and International Protection
- Likely part of a patent family seeking international protection via the Patent Cooperation Treaty (PCT).
- The scope in China is often aligned with or can be narrower/larger depending on strategic filing priorities.
Legal Status and Market Impact
- As of the latest update, the patent remains granted, offering market exclusivity for the protected formulation or compound within China.
- Enforceability depends on context, enforcement history, and potential litigation outcomes.
Strategic Considerations
Validity Challenges
- Opponents may argue prior art anticipation or obviousness.
- Patent holders should monitor scientific publications and existing patents for potential conflicts.
Litigation and Licensing
- The patent’s broad claims might be targeted for infringement suits.
- Licensing opportunities exist especially if the protected compound demonstrates significant therapeutic advantages.
Expiry and Lifecycle Management
- Patents filed in 2013 expire around 2033, culminating in lifecycle management strategies such as “patent term extensions” or “evergreening” (within legal bounds).
Conclusion
CN103254190 exemplifies a strategic patent covering a novel drug formulation or compound that, if well-crafted, provides robust protection within China's pharmaceutical patent landscape. Its scope emphasizes the importance of claim drafting that balances broad exclusivity with defensibility against invalidation. The patent's position within the competitive Chinese pharmaceutical patent landscape necessitates ongoing monitoring for infringement, potential invalidity challenges, and opportunities for licensing and market exclusivity extension.
Key Takeaways
- Scope Precision Matters: Well-drafted independent claims that cover core ingredients or methods provide a strong legal shield, but should be balanced against prior art constraints.
- Landscape Position: The patent is strategically positioned in a competitive environment with similar patents; enforcement and validity hinge on thorough prior art searches.
- Strategic Use: Exploiting this patent through licensing or commercialization can secure a dominant market position, while vigilant defense is vital.
- Lifecycle Management: Continuous innovation and filing strategies extend patent protection duration and market relevance.
- Legal Vigilance: Monitoring for potential invalidation or infringement is crucial, especially given the competitive Chinese drug patent landscape.
FAQs
1. What makes CN103254190 a significant patent in China’s pharmaceutical sector?
It claims a novel formulation or compound with potential therapeutic benefits, offering exclusivity that supports commercialization and market leadership pending validation of its claims against prior art.
2. How broad are the claims in CN103254190, and what does that imply?
The claims tend to be structured to encompass a wide range of formulations or compounds, providing the patent holder with a broad protective scope that reduces the likelihood of successful workarounds.
3. What common challenges could CN103254190 face in China’s patent system?
Potential challenges include prior art invalidation, obviousness assertions, or design-around strategies by competitors, especially if the core invention is incremental or narrowly defined.
4. How does the patent landscape in China influence the value of CN103254190?
China’s evolving patent environment means that innovation must be continually documented and defended rigorously, with a focus on maintaining validity amid a dense field of similar filings.
5. Can CN103254190 be enforced against international competitors?
Yes, provided they operate within China, and the patent is enforceable. For international enforcement, the patent’s Chinese protection needs to be complemented by international patent filings where applicable.
References
[1] State Intellectual Property Office of China (SIPO). Patent CN103254190 documentation.
[2] WIPO PatentScope Database (for filing and priority information).
[3] China Patent Law and Examination Guidelines.
[4] Industry reports on recent Chinese pharmaceutical patent trends.
